Business profile & competitive position
Healthpeak Properties, Inc. is an S&P 500 self-administered UPREIT classified under the Real Estate sector in the REIT - Healthcare Facilities industry. Through its operating subsidiary, Healthpeak OP, the company owns, operates, and develops U.S. healthcare real estate focused on discovery and delivery. As of December 31, 2025, the portfolio held interests in 689 properties split among outpatient medical buildings and hospitals, life-science lab buildings, senior housing, and a small set of non-reportable investments.
The scale and structure of that portfolio are the company's primary competitive anchors. Outpatient medical buildings accounted for 507 of the properties, and lab properties accounted for 145. According to the most recent 10-K, roughly 79% of outpatient medical square footage sits on or adjacent to hospital campuses, roughly 96% is affiliated with hospital systems, and roughly 72% is triple-net leased by leased square feet. The lab portfolio is even more heavily triple-net, at approximately 89%, and is geographically concentrated in three life-science hubs: San Francisco at 59% of square feet, Boston at 22%, and San Diego at 17%. The triple-net structure pushes operating-cost volatility to tenants, which can support steadier net operating income but also depends on tenant credit quality and lease rollover schedules.
Measured financially, the moat shows up as modest rather than dramatic: a net margin of 12.7% and an ROE of 5.0%. Those figures suggest the company converts revenue to profit, but not at a level that screams deep pricing power. In healthcare real estate, competitive advantage typically comes from location adjacency to major hospital systems, long-lease visibility, and tenant stickiness, and Healthpeak's hospital-campus positioning triple-net lease profile fit that pattern. Still, the 5.0% ROE is a reminder that capital intensity and debt service can compress returns on equity even for a large, diversified REIT.
Financial posture
Healthpeak Properties currently carries a $14.3B market capitalization and trades at a P/E ratio of 38.5. That multiple is well above what investors typically associate with income-oriented REITs, implying the market is pricing in above-trend growth, portfolio-quality scarcity, or a recovery in operating metrics. The net margin of 12.7% provides some profitability cushion, while the 5.0% ROE indicates that the company is earning a positive but not exceptional return for equity holders after accounting for its capital structure.
A beta of 0.99 places the stock roughly in line with the broad market's volatility, which is noteworthy for a real estate name. Many REITs carry betas above 1.0 because of rate sensitivity, so a beta just under 1.0 suggests DOC has traded with market-like volatility rather than exaggerated sensitivity to interest-rate swings. That said, the P/E of 38.5 combined with a 12.7% net margin means valuation is arguably demanding on a trailing earnings basis, and the gap between goodwill embedded in the stock price and the modest ROE is something readers should keep in mind when contextualizing the company's fundamentals.
Strategic priorities & outlook
Healthpeak's most recent 10-K outlines four operational priorities. First, the company intends to own, operate, and develop high-quality outpatient medical, lab, and senior housing real estate while managing the overall portfolio for long-term risk-adjusted returns and dividend growth. Second, it is committed to maintaining a strong investment-grade balance sheet with ample liquidity and primarily long-term fixed-rate debt with staggered maturities, explicitly to limit interest-rate and refinancing risk. Third, it plans to grow internally by working with tenants on space and capital needs, replacing tenants at favorable terms, extending or modifying leases prior to expiration, and providing property management that encourages renewals, expansions, and relocations. Fourth, Healthpeak aims to complete the proposed IPO of Janus Living in the first half of 2026 by contributing its 34-community senior housing portfolio, retaining a substantial majority ownership interest, and serving as the external manager.
The segment financials in the filing show where the money is coming from today. For 2025, segment Adjusted NOI was $795.8 million from outpatient medical, $567.4 million from lab, and $176.7 million from senior housing. That makes outpatient medical the cash-flow engine and lab the second-largest contributor. The Janus Living spin/IPO is the clearest near-term catalyst on the strategic side, since it would unlock a discrete capital-markets event for the senior housing segment while leaving Healthpeak with continued exposure through retained ownership and management fees.
Separately, in January 2026 the company acquired the remaining 46.5% interest in its SWF SH JV, taking full ownership of 19 senior housing properties. That move tightens control of a specific senior housing pool heading into the Janus Living transaction, and it shows management is actively consolidating interests around the senior housing segment rather than simply waiting for market conditions to improve.
Macro & geopolitical exposure
As a healthcare facilities REIT, Healthpeak's exposures map directly to the sector's core sensitivities. Interest rates are the most obvious macro variable, because REITs use debt to finance property acquisitions and because higher rates reduce the relative appeal of dividend yield versus fixed income. The company's stated use of long-term fixed-rate debt with staggered maturities is a direct hedge against that exposure.
Regulatory risk is also material, even though the REIT is a landlord rather than a care provider. Many of Healthpeak's healthcare tenants derive revenue from Medicare and Medicaid reimbursements, and changes to those programs can ripple through tenant credit quality, occupancy decisions, and rent coverage ratios. The life-science lab segment, meanwhile, is exposed to regional economic health in innovation clusters and to biotechnology funding cycles, particularly in San Francisco, Boston, and San Diego, where the lab portfolio is concentrated. Construction costs and supply-chain conditions matter for development projects, and labor availability can affect both senior housing operations and tenant build-outs. Currency exposure is limited because the portfolio is U.S.-focused.
Recent developments
The most recent headlines illustrate a mix of income positioning, peer comparison, institutional buying, and fundamental reassessment. On November 6, 2026, Seeking Alpha included Healthpeak in a "Safer Dividend Dogs" screen among S&P 500 names, which speaks to how income investors are currently framing the stock. On November 5, Defense World published a head-to-head comparison between American Healthcare REIT (NYSE:AHR) and Healthpeak, and separately reported that AIA Group Ltd purchased 109,929 shares of DOC. On November 4, Seeking Alpha ran a piece titled "Healthpeak Properties: FFO Is Down, But The Best Is Yet To Come," suggesting that at least one investing narrative is focused on forward fundamentals rather than trailing funds-from-operations weakness.
These items collectively show a stock being watched through two lenses: its yield and dividend safety relative to other large-cap real estate names, and the potential for an operational inflection tied to the Janus Living transaction, lease mark-to-market, and lab-market stabilization.
Earnings behavior & post-earnings drift
Healthpeak's recent earnings record is more volatile than the REIT label might suggest. Over the last eight reported quarters, the company has beaten estimates three times, for a beat rate of 38%, and the average earnings surprise across those quarters is just 1.1%. Those figures alone point to a company that is not consistently outpacing analyst models by a wide margin.
Despite the modest beat rate, the average 5-day price move after earnings across the same eight quarters is 5.23%, classified as an upward drift. That average is heavily influenced by one outsized event: the May 5, 2026 quarter, when DOC reported EPS of $0.28 against an estimate of $0.05276, a 430.7% positive surprise, and the stock jumped 18.11% the next day and 19.81% over the following five days. Without that quarter, the average drift would look materially different.
The more important lesson from the recent history is that beats have not reliably translated into sustained follow-through. The most recent report, on November 2, 2026, was a miss: EPS came in at $0.02 versus an estimate of $0.06355, a -68.5% surprise. The stock actually rose 0.41% the next day and 6.7% over the next five days, contradicting the simple "miss = selloff" script. The prior quarter, on August 4, 2026, was a beat: actual EPS of $0.08 versus an estimate of $0.02815, a 184.2% positive surprise, yet the stock gained only 0.79% the next day and then fell 5.13% over the following five days. The February 2, 2026 quarter was a -64.4% miss, with the stock falling 2.78% the next day and 0.47% over five days.
For the next scheduled report on February 1, 2027, after the market close, the consensus EPS estimate stands at $0.04386. The post-earnings record suggests that DOC's price reaction has been driven less by whether the company "beats" in a binary sense and more by the specific narrative around quarterly funds from operations, leasing momentum, and guidance. Readers should be cautious about assuming that a beat will produce a pop and hold, or that a miss guarantees a decline; the last two quarters alone show both assumptions can fail.
For a deeper look at how institutional research shops are currently modeling these cross-currents, readers can review the full institutional verdict on Healthpeak Properties.
Frequently Asked Questions
What does Healthpeak Properties actually own?
Healthpeak owns, operates, and develops U.S. healthcare real estate. As of December 31, 2025, its portfolio included interests in 689 properties across outpatient medical buildings and hospitals, lab and life-science buildings, senior housing, and a small number of other investments. The breakdown was 507 outpatient medical properties, 145 lab properties, 34 senior housing communities, and three non-reportable properties.
How profitable is Healthpeak based on the latest figures?
The company reported a net margin of 12.7% and a return on equity of 5.0%. It carries a $14.3 billion market capitalization and trades at a P/E of 38.5. The profitability is positive but modest, while the valuation multiple is elevated relative to traditional income REITs.
Does Healthpeak typically move higher after earnings?
Over the last eight reported quarters, the average 5-day move after earnings has been 5.23% to the upside, but that figure is skewed by an unusually strong May 2026 reaction. The beat rate is only 3 out of 8, and recent quarters show no reliable relationship between beating estimates and subsequent price direction. For example, the August 2026 beat was followed by a -5.13% five-day drift, while the November 2026 miss was followed by a +6.7% five-day drift.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-11-02 | $0.02 | $0.06355 | -68.5% | +0.41% | +6.7% |
| 2026-08-04 | $0.08 | $0.02815 | +184.2% | +0.79% | -5.13% |
| 2026-05-05 | $0.28 | $0.05276 | +430.7% | +18.11% | +19.81% |
| 2026-02-02 | $0.16 | $0.45 | -64.4% | -2.78% | -0.47% |
| 2025-10-23 | $-0.17 | $0.06 | -383.3% | - | - |
| 2025-07-24 | $0.05 | $0.06399 | -21.9% | - | - |
Previous DOC editions
Get the institutional verdict on DOC
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the DOC verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.